Abstract：
UNASSIGNED: Leukocytoclastic vasculitis (LCV) is a small vessel vasculitis involving arterioles, capillaries and postcapillary venules. LCV is generally confined to the skin, with extracutaneous manifestations occurring less frequently. LCV has multiple potential etiologies. Indeed, histological LCV can be found in anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis, immune complex vasculitis, vasculitis associated with systemic diseases (i.e. sarcoidosis, Sjögren\'s syndrome, rheumatoid arthritis, and systemic lupus erythematosus), or in vasculitis associated with cancer, infections, sepsis and use of certain medications. LCV can also be idiopathic in up to 50% of cases.
UNASSIGNED: Semaglutide is a glucagon-like peptide 1 (GLP-1) receptor agonist used for management of type 2 diabetes mellitus (T2DM), obesity and overweight associated with one or more weight-related comorbidities. A case of drug-induced LCV has already been described with the use of once-daily oral semaglutide. Herein, we describe the first case of skin-limited LCV induced by once-weekly subcutaneous semaglutide in a 73-year-old man with T2DM, who experienced the complete resolution of the skin lesions shortly after the discontinuation of semaglutide therapy.
UNASSIGNED: Future prospective studies, adverse event reporting and post-marketing surveillance will certainly contribute to establishing if LCV represents a less rare than expected side effect of both oral and subcutaneous semaglutide formulations.
UNASSIGNED: Semaglutide is a glucagon-like peptide 1 (GLP-1) receptor agonist used for management of type 2 diabetes mellitus (T2DM), obesity and overweight associated with one or more weight-related comorbidities. A case of drug-induced LCV has already been described with the use of once-daily oral semaglutide. Herein, we describe the first case of skin-limited LCV induced by once-weekly subcutaneous semaglutide in a 73-year-old man with T2DM, who experienced the complete resolution of the skin lesions shortly after the discontinuation of semaglutide therapy.
UNASSIGNED: Future prospective studies, adverse event reporting and post-marketing surveillance will certainly contribute to establishing if LCV represents a less rare than expected side effect of both oral and subcutaneous semaglutide formulations.
摘要：
简介：白细胞碎裂性血管炎（LCV）是一种累及小动脉的小血管血管炎，毛细血管和毛细血管后小静脉。LCV通常局限于皮肤，皮肤外表现发生频率较低。LCV具有多种潜在病因。的确,组织学LCV可以在抗中性粒细胞胞浆抗体（ANCA）相关血管炎中发现，免疫复合物血管炎，与全身性疾病相关的血管炎(即，结节病,干燥综合征,类风湿性关节炎,和系统性红斑狼疮)，或与癌症相关的血管炎，感染,败血症和某些药物的使用。LCV在高达50%的病例中也可以是特发性的。病例报告：塞马鲁肽是一种胰高血糖素样肽1（GLP-1）受体激动剂，用于治疗2型糖尿病（T2DM）。已经描述了使用每日一次口服司马鲁肽的药物诱导的LCV病例。在这里，我们描述了在一名73岁的T2DM患者中，由每周一次皮下semaglutide诱导的第一例皮肤受限LCV，在停止司马鲁肽治疗后不久，皮肤病变完全消退。结论：未来的前瞻性研究，不良事件报告和上市后监测肯定有助于确定LCV是否比口服和皮下司马鲁肽制剂的副作用少。
